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Background: CF infants may be at increased risk of sodium depletion which may lead to impaired growth. The objective of this study was to
evaluate their sodium supplementation requirements.
Methods: Ten CF infants had serial measurements of weight and plasma/urine sodium and creatinine. Sodium supplementation was adjusted with
the aim of maintaining fractional excretion (FENa) between 0.5% and 1.5% and urinary sodiumN10 mmol/L.
Results: Urine sodium:creatinine (UNa:Cr) ratio strongly correlated with FENa [UNa:Cr (mmol/mmol)=35.0×FENa (r=0.99)]. The FENa target
range corresponded to UNa:Cr 17–52 mmol/mmol. All infants required sodium supplementation to achieve UNa:Cr N17 mmol/mmol. Sodium
supplement requirements (mean±SD) at ages 0–3, 3–6, 6–9 and 9–12 months were 1.9±0.5, 1.8±0.8, 1.9±0.9 and 0.8±0.4 mmol/kg/d. No
infant required calorie supplementation to achieve expected weight gain.
Conclusions: Using current UK guidelines, many cases of sodium depletion may be overlooked. Some infants require more than the recommended
1–2 mmol/kg/d. UNa:Cr ratio is a useful non-invasive measure to monitor sodium supplementation.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Sodium supplementation; Urinary sodium excretion1. Background
Current UK and European guidelines suggest that infants
with CF do not require routine sodium supplementation, but
may benefit from sodium supplementation at high ambient
temperatures or with increased water losses due to fever, diar-
rhoea or tachypnoea [1,2]. However, there is evidence based on
case reports that the sodium content of breast milk and infant
formula may often be inadequate for requirements of CF infants
[3] and sodium depletion may occur even when the infant is not
exposed to heat stress [4]. This may lead to chronic secondary
hyperaldosteronism and consequent impaired growth [5–9].
Plasma sodium is an insensitive marker of sodium depletion
and may also be affected by hydration state. A urine sodium
concentration of b10 mmol/L has been quoted as an indicator of⁎ Corresponding author. Department of Nutrition and Dietetics, Royal Hospital
for Sick Children, Edinburgh EH9 1LF, UK. Tel.: +44 131 536 0301.
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doi:10.1016/j.jcf.2009.08.006sodium depletion in CF infants in a UK consensus report [2] and
is supported by a small study of sodium requirements for
growth in 11 non-CF infants with ileostomies [10]. However
urine sodium concentration is highly dependent on urine flow
rate and its use as an indicator may be misleading. Fractional
excretion of sodium in relation to creatinine (FENa) is theo-
retically a more appropriate marker of sodium depletion that
compensates for urine flow rate, but requires paired blood
and urine samples. Potentially, the urinary sodium:creatinine
ratio (UNa:Cr ratio) might be a less invasive marker of sodium
depletion while still compensating for urine flow rate, but
there are no published studies relating this ratio to FENa in
children.
In our tertiary paediatric referral centre, our routine practice
has been to give sodium supplementation to infants with CF,
based on a combination of urinary sodium concentration and
FENa. Here we report an observational study of a cohort of
10 sodium-supplemented infants with newly diagnosed CF
followed longitudinally over the first year of life. Our aims were
to evaluate (1) whether a urinary marker of sodium status could
act as a surrogate for the ‘gold standard’ of FENa, (2) sodiumd by Elsevier B.V. All rights reserved.
Fig. 1. Weight gain over the first year of life in 10 salt-supplemented CF infants
(mean and range, hatched bars) comparedwith expectedweight gain based on growth
charts in age-matched healthy infants (median and 3rd to 97th centiles, unhatched
bars) [12].
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infants over the first year of life.
2. Methods
The inclusion criteria for the study were infants with newly
diagnosed CF referred to our tertiary CF referral centre, who
required pancreatic enzyme replacement therapy (PERT). Infants
were identified through the Scottish neonatal screening pro-
gramme. All included infants had a positive sweat test (sweat
chloride N60 mmol/L). Requirement for PERT was confirmed by
a low faecal pancreatic elastase (b120 μg/g stool). None of the
infants had an ileostomy, and none were febrile at the time
measurements were taken. We excluded one CF infant with short
bowel syndrome requiring prolonged parenteral nutrition.
This was an observational study of current practice in the
Cystic Fibrosis clinic. Formal consent was not requested of
families to have their data included in the study.
The infants were studied longitudinally over the first year of
life. At each clinic visit, the infant (undressed) was weighed using
NBS-30 series Weymed scales. Urine and, where possible, a
paired blood sample were also collected for sodium and creati-
nine measurement. In a sub-set of five patients receiving sodium
supplementation, additional blood samples were collected for
plasma renin activity and aldosterone and stored at −20 °C until
analysis.
Sodium and creatinine were measured by standard laboratory
methods. The paediatric reference range for plasma sodium was
132–144 mmol/L. Renin activity was measured by radioimmu-
noassay of generated angiotensin I (Renin MAIA™, Adaltis,
Montreal, Canada). Aldosterone was measured by radioimmu-
noassay (Coat-A-Count® Aldosterone, DPC, LosAngeles, USA).
Results were compared with our laboratory reference ranges for
infants aged 1 month to 1 year: 0.8–30 ng/mL/h for renin activity
and 100–4500 pmol/L for aldosterone.
Sodium excretion was expressed as urine sodium concen-
tration (mmol/L), as UNa:Cr ratio (mmol/mmol) and as FENa
using the formula:
FENa =
Urinary sodiumðmmol=LÞ
Plasmasodiumðmmol=LÞ ×
Plasmacreatinineðmmol=LÞ
Urinarycreatinineðmmol=LÞ × 100%
Sodium chloride supplementation was adjusted with the aim
of maintaining FENa between 0.5% and 1.5% and urinary
sodiumN10 mmol/L. The target range for FENa was chosen
pragmatically, based on published data in normal infants and
children [11]. The lower limit of the target range corresponds
to the mean FENa reported in 8 normal infants and the upper
limit to the mean+2SD in 50 normal children [11]. Supple-
mentary sodium was given using sodium chloride solution
(1 mmol/ml). Starting doses for sodium chloride were calculat-
ed based on 1–2 mmol/kg body weight per day, taking into
account the infant's initial FENa measurement. Advice given
to parents for supplementation at each clinic visit (the recom-
mended sodium requirement) was in the form of the volume of
sodium chloride solution to be added to each feed (for bottle-fed
infants) or as doses of sodium chloride solution (for breast-fedinfants). Thereafter sodium chloride supplementation was main-
tained, increased or reduced according to whether infants had a
UNa:Cr ratio within, below or above the target range.
Weight gain in CF infants during the first year of life was
compared with expected weight gain in age-matched healthy
infants using growth charts based on longitudinal data [12].
Results were expressed as mean±SD, unless otherwise stated.
Changes through time were evaluated by one-way repeated mea-
sures analysis of variance. Statistical analyses were performed
using Analyse-it software (v2.03).
3. Results
Ten newly diagnosed infants with CF (5 males, 5 females)
requiring PERT participated in the study. Age at referral was
4.5±2.4 weeks. Fig. 1 illustrates actual versus expected weight
gain for this cohort of sodium-supplemented CF infants. Weight
gain over the first year was within the expected range for age
and no infant required calorie supplementation.
During the study, 83 urine samples and 50 paired blood
samples were collected from the 10 infants. In the urine sam-
ples, the correlation between urinary sodium concentration and
UNa:Cr ratio was influenced by the variable urine flow rate
(r=0.62). In the paired blood and urine samples, a similar
correlation between urinary sodium concentration and FENa
was observed (r=0.68). By contrast, UNa:Cr ratio correlated
very highly with FENa (r=0.99, Fig. 2). The regression line
between the two calculated variables was: UNa:Cr ratio (mmol/
mmol)=35.0×FENa (%). The target FENa range of 0.5–1.5%
therefore corresponded to a UNa:Cr ratio range of 17–52 mmol/
mmol, which was subsequently used as the target range for salt
supplementation.
Before sodium supplementation began, only one infant with
meconium ileus was hyponatraemic (plasma sodium 126 mmol/L)
in the first week of life. However, before supplementation started
CF infants had a low urine sodium concentration of 6±5 mmol/L
and a low UNa:Cr ratio of 11.2±7.0 mmol/mmol (equivalent to
FENa 0.32±0.20%).
All 10 infants required sodium supplementation to achieve urine
sodium concentrations N10 mmol/L and UNa:Cr ratio N17 mmol/
Fig. 2. Relationship of urine sodium:creatinine ratio (mmol/mmol, y) to FENa (%, x)
in 50 paired plasma and urine samples from 10 infants with CF: y=35.0x (r=0.99).
The target FENa of 0.5%–1.5% corresponded to a urine sodium:creatinine ratio of
17–52 mmol/mmol, shown by the dashed lines.
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ded sodium chloride supplementation at 0–3, 3–6, 6–9 and 9–
12 months of age were 1.9 (1.2–2.6), 1.8 (0.7–3.6), 1.9 (0.8–3.0)
and 0.8 (0.2–1.5) mmol/kg/d (P=0.003). Requirements decreased
at 9–12 months as infants took more salt-containing solid foods
in their diet. Actual intakes of sodium supplements (as reported
by parents at the next clinic visit) were 1.6 (0.8–2.4), 1.5 (0.7–3.2),
1.8 (0.8–3.9) and 1.1 (0.6–1.9) mmol/kg/d respectively (P=0.2).
UNa:Cr ratios were 23.5±11.9, 15.8±8.5, 27.5±17.8 and 42.1±
15.5 mmol/mmol respectively (P=0.04). UNa:Cr ratio was higher
in the 9–12 month age group, despite lower supplementation,
reflecting increased salt intake from solid food.
Overall, during salt supplementation 75%of urine samples had
sodium concentrations≥10 mmol/L. UNa:Cr ratio was within
the target range of 17–52 mmol/mmol in 45% of urine samples,
below the target range in 44% and above the target range in 11%.
For those samples with UNa:Cr ratio above the target range, the
increase was usually mild and transient and supplements were
reduced accordingly. One infant had a maximumUNa:Cr ratio of
124 mmol/mmol (FENa 3.5%), which did not reflect her recom-
mended supplements and was traced to a compound alginate
preparation [Infant Gaviscon] which she was receiving for reflux
(0.92 mmol sodium per dose, intake from this source up to
2.0 mmol/kg/d). This infant became briefly slightly hypernatrae-
mic whilst unwell (plasma sodium 148 mmol/L) and sodium
supplements were stopped. No infant became hyponatraemic
during supplementation.
In 8 samples from 5 CF infants collected at 23±9 weeks of
age during sodium supplementation (1.0±0.8 mmol/kg/d), renin
activity was 4.4±3.0 ng/mL/h (range 2.1–10.3 ng/mL/h) and
aldosterone was 880±579 pmol/L (range 130–1770 pmol/L),
within the reference range for age in all infants.
4. Discussion
With the widespread introduction of neonatal screening
programmes for CF, more infants are being diagnosed in early
infancy. Although these infants are potentially at increased riskof sodium depletion compared with normal infants, owing to the
relatively low salt content of human breast milk and formula
milk, there is a lack of evidence-based guidelines regarding any
requirement for routine sodium supplementation. Whilst one
consensus report in North America recommended supplemental
sodium for babies with CF before introduction of complemen-
tary foods/weaning diet [13], there is presently a lack of spe-
cific guidance on evaluation of sodium depletion in relation
to sodium supplementation for CF infants [1,2,13]. Recent UK
practice has been to consider the possibility of sodium defi-
ciency by checking urinary sodium levels only if plasma so-
dium is low, growth is poor or the infant has a stoma (Personal
communication with other UK CF centres – 2005). Results
from our study indicate that, using these criteria, many cases of
sodium depletion may be overlooked.
It is widely recognized that hyponatraemia is an insensitive and
late manifestation of sodium depletion. In CF patients, even during
sodium depletion resulting in volume contraction and vigorous
activation of the renin-aldosterone axis, plasma sodium often
remains normal [6,9]. Even when sodium-replete, CF adolescents
may have evidence of chronic secondary hyperaldosteronism [9].
However, it would be impractical to use renin/aldosterone mea-
surements for routine monitoring of sodium status in CF infants
owing to the relatively large blood volumes required, sample
handling issues,wide reference ranges in infants, expense and delay
in obtaining results for these specialized tests. Theoretically, the
best measure of sodium repletion or depletion is FENa, but ref-
erence data in infants and children are limited. We chose FENa
target limits pragmatically based on the reported mean for a small
group of normal infants and the mean+2SD for a larger group of
normal children [11], with the two-fold aim of achieving sufficient
sodium replacement but avoiding over-replacement and potential
salt poisoning. As expected, the correlation between urine sodium
concentration and FENa was influenced by the variable urine flow
rate (r=0.68). Although correlations of this magnitude might be
considered acceptable for a group, they result in less accurate
predictions for an individual infant. By contrast, UNa:Cr ratio
correlated very highly with FENa because it compensated for
urinary flow rate. This allowed us to use non-invasive randomurine
samples to monitor sodium status, using a target range for UNa:Cr
ratio based on its regression with FENa.
Before supplementation, most CF infants in our cohort were
sodium deficient according to our criteria and all required so-
dium supplementation to achieve UNa:Cr ratios within the target
range. Even during supplementation, UNa:Cr ratio was below
the target in 44% urine samples. This is likely to be a result of
our centre's policy for advice to parents regarding sodium doses;
rather than doses per kg body weight, sodium is prescribed as
doses of sodium chloride solution per feed (for bottle-fed infants)
or as a number of doses per day (for breast-fed infants). This is a
pragmatic approach to reduce risk of dosage error, but in periods
of rapid growth or when a bottle-fed infant is taking a smaller
number of higher volume feeds, it results in a reduction of so-
dium given per kg body weight for infants between clinic visits.
Importantly, over-supplementation was largely avoided, with
UNa:Cr ratio increased above the target range in only 11% urine
samples, usually only transiently andmildly except for one patient
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unrecognized source of sodium. This infant developed a transient
mild hypernatraemia. One outcome of this study is therefore that
supplementation should take into account any other potential
sources of sodium. To avoid over-supplementation, we would
also recommend that the salt intake from the infant's weaning diet
is regularly assessed and taken into account. In a sub-set of salt-
supplemented infants, there was no evidence of either excessive
activation or suppression of the renin-aldosterone axis, suggesting
that the target range chosen was appropriate.
When sodium depletion is identified, current UK guidelines
recommend correction with 1–2 mmol/kg/d sodium chloride
[2]. Our results suggest that in some infants, 2–3 mmol/kg/d
may be required up to the age of 9 months, but the amount
required usually decreases between 9 and 12 months of age as
the infant takes more salt-containing solid foods in their diet.
In our study cohort, all CF infants had good weight gain,
possibly due to the permissive role of their sodium-replete
status. However, a randomized control trial would be required
to confirm whether or not salt-supplemented CF infants have
better weight gain than unsupplemented CF infants.
This study has several limitations. Firstly, it was an evaluation
of current local practice, with no unsupplemented control group,
not a randomized control trial. Secondly, the number of infants
was small. Thirdly, the choice of target limits for FENa on which
to base sodium supplementation was essentially pragmatic, based
on limited published data, and it was beyond the scope of the
study to evaluate these limits systematically using serial renin/
aldosterone measurements. Nevertheless, our study may have
significant clinical implications and may provide valuable data to
inform any future randomized control trials. Further studies on
assessment of sodium depletion, sodium supplementation and
the impact on weight gain in CF infants are warranted.
An important finding from our study is the strong correlation
between FENa and UNa:Cr ratio. We conclude that UNa:Cr
ratio is a useful non-invasive measure of the adequacy of so-
dium supplementation in CF infants. UNa:Cr ratio should be
routinely checked before considering energy supplements andcan be used for the routine monitoring of sodium supplemen-
tation in CF infants.Acknowledgement
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